| bibliographicCitation |
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang T, Liang X, Chen C, Wang L, Cheng A, Kaseb A, Vogel A, Qin S, Chan SL, Cheng A, Kaseb A, Vogel A, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang T, Liang X, Chen C, Wang L, Zhang M, Xu L, Yuan X, Li D, Ying J, Zhang J, Zhang T, Gu K, He Y, Hao P, Jiang D, Zhang S, Xing B, Zhang B, Wang D, Zhai X, Liang H, Cybulska-Stopa B, Dvorkin M, Stroyakovskiy D, Nechaeva M, Yen C, Su W, Chen Y, Bondarenko I, Yang L, Fang W, Gomez-Martin C, Ryu M, Kim H, Kim J, Zarubenkov O, Orlova R, Poddubskaya E, Fadeeva N, Makarova Y, Chao Y, Hung C, Neffa M, Vynnychenko O, Burgoyne A, Hao C, Mohr RU, Diaz-Beveridge R, Feliu-Batlle J, Cubillo-Gracian A, Lee A, Daniele B, Antonuzzo L, Sangiovanni A, Gasbarrini A, Scartozzi M, Ahn MS, Oh S, Orlov S, Harputluoglu H, Oksuzoglu B, Hsu C, Rau K, Krechkovskyi O, Yareshko V, Xiong H, Lee F, Jiang Y, Gabayan A, Crow M, Van Steenkiste C, Verset G. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. The Lancet. 2023 Sep;402(10408):1133–46. doi: 10.1016/s0140-6736(23)00961-3. |